Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway

Figure 4

Lenvatinib-alisertib combination inhibits DNA damage signaling pathways in HCC cells. (a) HepG2 and Hep3B cells were treated with lenvatinib, alisertib, or both for 48 hr. Western blotting was then conducted to monitor the expression of AURKA, p-AURKA, p-ATR, p-ATM, p-BRCA1, p-Chk1, p-Chk2, and γ-H2AX in the cells. (b, c) HepG2 and Hep3B cells were treated with lenvatinib, alisertib, or both for 48 hr. Immunofluorescent staining of γ-H2AX or p-ATM and confocal microscopy analysis of the number of γ-H2AX foci was performed.

(a)

(b)

(c)